Business Context and Reporting Period
This Form 8-K is a current report filed by NeuroBo Pharmaceuticals, Inc. (not Metavia Inc.) on December 19, 2023. The filing addresses a material modification to the rights of security holders regarding a reverse stock split approved to maintain compliance with Nasdaq listing requirements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split: The Board of Directors approved a 1-for-8 reverse stock split of the Company's issued and outstanding Common Stock.
- Effective Date: The split became effective at 5:00 p.m. Eastern Time on December 20, 2023.
- Trading Resumption: Common Stock began trading on a split-adjusted basis on Nasdaq on December 21, 2023, under the symbol NRBO.
- Fractional Shares: Fractional shares resulting from the split are rounded down, with cash paid in lieu of fractions based on the closing sales price on the last trading day before effectiveness.
- Equity Adjustments: Proportionate adjustments were made to the exercise prices and share counts for outstanding stock options, restricted stock units, and warrants.
- Identification: The new CUSIP number for the Common Stock is 64132R404.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the context of maintaining Nasdaq listing compliance. The primary contingency addressed is the successful implementation of the reverse split to avoid delisting.
Investor Verification Checklist
- Verify the new CUSIP number (64132R404) for trading and record-keeping purposes.
- Confirm the adjusted share count and exercise prices for any held options, RSUs, or warrants.
- Check brokerage statements for the receipt of cash in lieu of fractional shares.
- Review the Company's Definitive Proxy Statement (Schedule 14A) filed on May 26, 2023, for detailed background on the split proposal.